Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) will report third quarter 2025 financial results before U.S. market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights.
Investors can access the live webcast via the company's Investor Relations site at ir.neogenomics.com. The webcast will be archived and available for replay. To join by phone, dial (888) 506-0062 (U.S.) or (973) 528-0011 (international) and use participant code 392611.
NeoGenomics (NASDAQ:NEO) has secured a significant legal victory as the District Court for the Middle District of North Carolina granted summary judgment in its patent infringement lawsuit against Natera. The Court ruled that Natera's asserted patent claims are invalid for claiming ineligible subject matter.
This ruling allows NeoGenomics to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States. The company has already launched RaDaR ST to biopharma customers and has submitted for clinical reimbursement coverage through CMS's MolDX program.
NeoGenomics (NASDAQ: NEO) has launched NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test designed for advanced solid tumors. The new test analyzes over 500 genes, including MSI and bTMB markers, with a 7-day turnaround time.
PanTracer LBx enables therapy selection, trial matching, and disease monitoring through a simple blood draw when tissue samples are limited or unavailable. This strategic launch positions NeoGenomics in the $3-5 billion liquid biopsy market, complementing their existing tissue-based testing portfolio and expanding their addressable market.
NeoGenomics (NASDAQ: NEO) reported Q2 2025 results with consolidated revenue increasing 10% to $181 million. Clinical revenue grew 16%, with 13% growth excluding the Pathline acquisition. The company's average revenue per clinical test increased 2% to $465, driven by higher-value tests and strategic reimbursement initiatives.
Despite revenue growth, NEO reported a net loss of $45 million, up 142% year-over-year, primarily due to $20 million in impairment charges. Adjusted EBITDA remained relatively flat at $10.7 million. The company completed the acquisition of Pathline for $8 million plus contingent consideration.
NeoGenomics revised its full-year 2025 guidance downward, now expecting revenue of $720-726 million (9-10% growth) and increased net loss projections to $108-116 million, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch.
NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its second quarter 2025 financial results announcement for July 29, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants can dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 859170.
NeoGenomics (NASDAQ: NEO) has launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, along with PanTracer Tissue + HRD option for enhanced tumor analysis. The new assay evaluates over 500 cancer-related genes and can deliver results in as little as 8 days.
PanTracer Tissue + HRD specifically targets ovarian cancer diagnostics by incorporating homologous recombination deficiency analysis, BRCA mutation status, and genomic instability score in a single test. These biomarkers are crucial for guiding PARP inhibitor treatments and therapies targeting DNA repair pathways.
The new offerings, revealed at the 2025 ASCO Annual Meeting, represent an upgrade to the company's previous NeoComprehensive® Solid Tumor platform, featuring minimal specimen requirements and alignment with clinical guidelines for therapy selection and clinical trial enrollment.
NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has appointed Dr. Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green currently serves as Senior Vice President and Head of Oncology, Global Clinical Development at Merck, overseeing the company's largest commercial revenue and pipeline investment area.
Dr. Green brings extensive experience in clinical oncology and pipeline development, having previously held leadership positions at Seagen and Genentech. She began her career as a Medical Oncologist at MD Anderson Cancer Center, where she later became Medical Director of the Nellie B. Connally Breast Center.
NeoGenomics (NASDAQ:NEO) is set to unveil its PanTracer™ Family of genomic profiling tests and Paletrra™ spatial proteomics platform at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3, 2025). The PanTracer suite includes three tests: PanTracer™ Tissue for comprehensive tumor profiling, PanTracer™ LBx for liquid biopsy applications, and PanTracer™ Tissue + HRD for homologous recombination deficiency testing.
Paletrra, an AI-powered platform, transforms tissue samples into high-plex, image-based insights for translational research teams. The company will showcase these solutions at Booth #11093, featuring an interactive "Hey Neo" experience. Additionally, NeoGenomics will present research findings through one poster presentation and two online abstracts, focusing on folate receptor alpha expression, cancer fusionome analysis, and PanTracer LBx validation.
NeoGenomics (NASDAQ:NEO), a leading oncology testing services company, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 1:00 pm ET, followed by a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4 at 2:00 pm ET. Both sessions will be available via webcast, accessible through the company's Investor Relations website at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO), an oncology testing services provider, has announced the complete repayment of its $201.25 million outstanding 1.25% Convertible Senior Notes that were due to mature on May 1, 2025. The company utilized its available cash reserves to fully settle this debt obligation.